T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Authors:
Steven M. Horwitz Memorial Sloan Kettering Cancer Center;

Search for other papers by Steven M. Horwitz in
Current site
Google Scholar
PubMed Close
 MD
,
Stephen Ansell Mayo Clinic Cancer Center;

Search for other papers by Stephen Ansell in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Weiyun Z. Ai UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Weiyun Z. Ai in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Jeffrey Barnes Massachusetts General Hospital Cancer Center;

Search for other papers by Jeffrey Barnes in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Stefan K. Barta Abramson Cancer Center at the University of Pennsylvania;

Search for other papers by Stefan K. Barta in
Current site
Google Scholar
PubMed Close
 MD, MRCP, MS
,
Jonathan Brammer The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Jonathan Brammer in
Current site
Google Scholar
PubMed Close
 MD
,
Mark W. Clemens The University of Texas MD Anderson Cancer Center;

Search for other papers by Mark W. Clemens in
Current site
Google Scholar
PubMed Close
 MD
,
Ahmet Dogan Memorial Sloan Kettering Cancer Center;

Search for other papers by Ahmet Dogan in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Francine Foss Yale Cancer Center/Smilow Cancer Hospital;

Search for other papers by Francine Foss in
Current site
Google Scholar
PubMed Close
 MD
,
Paola Ghione Roswell Park Comprehensive Cancer Center;

Search for other papers by Paola Ghione in
Current site
Google Scholar
PubMed Close
 MD
,
Aaron M. Goodman UC San Diego Moores Cancer Center;

Search for other papers by Aaron M. Goodman in
Current site
Google Scholar
PubMed Close
 MD
,
Joan Guitart Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Joan Guitart in
Current site
Google Scholar
PubMed Close
 MD
,
Ahmad Halwani Huntsman Cancer Institute at the University of Utah;

Search for other papers by Ahmad Halwani in
Current site
Google Scholar
PubMed Close
 MD
,
Bradley M. Haverkos University of Colorado Cancer Center;

Search for other papers by Bradley M. Haverkos in
Current site
Google Scholar
PubMed Close
 MD, MPH, MS
,
Richard T. Hoppe Stanford Cancer Institute;

Search for other papers by Richard T. Hoppe in
Current site
Google Scholar
PubMed Close
 MD
,
Eric Jacobsen Dana-Farber/Brigham and Women's Cancer Center;

Search for other papers by Eric Jacobsen in
Current site
Google Scholar
PubMed Close
 MD
,
Deepa Jagadeesh Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Deepa Jagadeesh in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Allison Jones St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

Search for other papers by Allison Jones in
Current site
Google Scholar
PubMed Close
 MD
,
Avyakta Kallam Fred & Pamela Buffett Cancer Center;

Search for other papers by Avyakta Kallam in
Current site
Google Scholar
PubMed Close
 MD, MBBS
,
Youn H. Kim Stanford Cancer Institute;

Search for other papers by Youn H. Kim in
Current site
Google Scholar
PubMed Close
 MD
,
Kiran Kumar UT Southwestern Simmons Comprehensive Cancer Center;

Search for other papers by Kiran Kumar in
Current site
Google Scholar
PubMed Close
 MD, MBA
,
Neha Mehta-Shah Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Neha Mehta-Shah in
Current site
Google Scholar
PubMed Close
 MD, MSCI
,
Elise A. Olsen Duke Cancer Institute;

Search for other papers by Elise A. Olsen in
Current site
Google Scholar
PubMed Close
 MD
,
Saurabh A. Rajguru University of Wisconsin Carbone Cancer Center;

Search for other papers by Saurabh A. Rajguru in
Current site
Google Scholar
PubMed Close
 MD
,
Sima Rozati The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Sima Rozati in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Jonathan Said UCLA Jonsson Comprehensive Cancer Center;

Search for other papers by Jonathan Said in
Current site
Google Scholar
PubMed Close
 MD
,
Aaron Shaver Vanderbilt-Ingram Cancer Center;

Search for other papers by Aaron Shaver in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Lauren Shea O'Neal Comprehensive Cancer Center at UAB;

Search for other papers by Lauren Shea in
Current site
Google Scholar
PubMed Close
 MD
,
Michi M. Shinohara Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

Search for other papers by Michi M. Shinohara in
Current site
Google Scholar
PubMed Close
 MD
,
Lubomir Sokol Moffitt Cancer Center;

Search for other papers by Lubomir Sokol in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Carlos Torres-Cabala The University of Texas MD Anderson Cancer Center;

Search for other papers by Carlos Torres-Cabala in
Current site
Google Scholar
PubMed Close
 MD
,
Ryan Wilcox University of Michigan Rogel Cancer Center;

Search for other papers by Ryan Wilcox in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Peggy Wu UC Davis Comprehensive Cancer Center;

Search for other papers by Peggy Wu in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Jasmine Zain City of Hope National Medical Center; and

Search for other papers by Jasmine Zain in
Current site
Google Scholar
PubMed Close
 MD
,
Mary Dwyer National Comprehensive Cancer Network.

Search for other papers by Mary Dwyer in
Current site
Google Scholar
PubMed Close
 MS
, and
Hema Sundar National Comprehensive Cancer Network.

Search for other papers by Hema Sundar in
Current site
Google Scholar
PubMed Close
 PhD
Volume/Issue:
Volume 20: Issue 3
Online Publication Date:
Mar 2022
DOI:
https://doi.org/10.6004/jnccn.2022.0015
Restricted access

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase–positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase–negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Individual Disclosures for the NCCN T-Cell Lymphomas Panel
Individual Disclosures for the NCCN T-Cell Lymphomas Panel

  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909–3918.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Swerdlow SH, Harris NL, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: IARC;. 2017.

  • 4.

    Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92:76–82.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467–1475.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014;123:2915–2923.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood 2014;123:3007–3015.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 2019;133:1664–1676.

  • 9.

    Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood 2019;134:2159–2170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Xie Y, Jaffe ES. How I diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 2021;156:1–14.

  • 11.

    Zettl A, Lee SS, Rüdiger T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002;117:368–379.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Willenbrock K, Bräuninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 2007;138:733–739.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 2008;111:4463–4470.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697–2706.

  • 15.

    Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402–3408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124:1473–1480.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood 2017;130:554–557.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Luchtel RA, Dasari S, Oishi N, et al. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 2018;132:1386–1398.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Hapgood G, Ben-Neriah S, Mottok A, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol 2019;186:e28–e31.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000;18:795–803.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Wöhrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol 2004;15:1680–1683.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Babel N, Paragi P, Chamberlain RS. Management of enteropathy-associated T-cell lymphoma: an algorithmic approach. Case Rep Oncol 2009;2:36–43.

  • 23.

    Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011;118:148–155.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913–3921.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496–5504.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Sibon D, Fournier M, Brière J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 2012;30:3939–3946.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014;25:2211–2217.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Gleeson M, Peckitt C, Cunningham D, et al. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. Leuk Lymphoma 2018;59:1586–1595.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Shustov A, Cabrera ME, Civallero M, et al. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. Blood Adv 2021;5:640–648.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood 2021;138:213–220.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    López-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998;9:849–855.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474–2479.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Federico M, Bellei M, Marcheselli L, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS): a new prognostic model developed by the International T cell Project Network. Br J Haematol 2018;181:760–769.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Ellin F, Maurer MJ, Srour L, et al. Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. Br J Haematol 2019;186:e24–e27.

  • 35.

    Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol 2017;35:4019–4026.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Suzuki Y, Yano T, Suehiro Y, et al. Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma. Int J Hematol 2020;112:817–824.

  • 37.

    Kim YR, Kim SJ, Lee HS, et al. Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-cell Lymphoma: a Retrospective Study [published online August 5, 2021]. Cancer Res Treat. DOI: 10.4143/crt.2021.270

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Shirouchi Y, Yokoyama M, Fukuta T, et al. Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. Leuk Lymphoma 2021;62:1869–1876.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 2013;98:e81–e82.

  • 40.

    Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2006;2006:317–322.

  • 41.

    Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 2006;30:490–494.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Grogg KL, Attygalle AD, Macon WR, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 2006;19:1101–1107.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Dobay MP, Lemonnier F, Missiaglia E, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica 2017;102:e148–e151.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Carson KR, Horwitz SM, Pinter-Brown LC, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer 2017;123:1174–1183.

  • 45.

    Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104: 626–633.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418–3425.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Cederleuf H, Bjerregård Pedersen M, Jerkeman M, et al. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. Br J Haematol 2017;178:739–746.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Dunleavy K, Pittaluga S, Shovlin M, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica 2016;101:e27–e29.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Maeda Y, Nishimori H, Yoshida I, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica 2017;102:2097–2103.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Escalón MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103:2091–2098.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Wulf GG, Altmann B, Ziepert M, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia 2021;35:143–155.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Bachy E, Camus V, Thieblemont C, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol 2022;40:242–251.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Ghione P, Faruque P, Mehta-Shah N, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv 2020;4:4640–4647.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021;137:2161–2170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Ruan J, Moskowitz AJ, Mehta-Shah N, et al. Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment of peripheral T-cell lymphoma (PTCL) [abstract]. Blood 2020;136(Supplement 1): 33–34.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019;393: 229–240.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Horwitz SM, O’Connor OA, Pro B, et al. The Echelon-2 Trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma [abstract]. Blood 2020;136(Supplement 1):3–5.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Jagadeesh D, Horwitz SM, Bartlett NL, et al. Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas [abstract]. J Clin Oncol 2019;37:7543. (Abstract 7543)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115:3664–3670.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88:1272–1278.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533–1538.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Rodríguez J, Conde E, Gutiérrez A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007;78:290–296.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 2007;136:111–113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19:958–963.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218–224.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Reimer P, Rüdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106–113.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    d'Amore F, Relander T, Lauritzsen GF, et al. Ten years median follow-up of the NORDIC NLG-T-01 trial on CHOEP and upfront autologous transplantation in peripheral T-cell lymphomas [abstract]. Hematol Oncol 2015;33 (Suppl S1):Abstract 074.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014;124:1570–1577.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Nijeboer P, de Baaij LR, Visser O, et al. Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort. Am J Hematol 2015;90:493–498.

  • 70.

    Phillips EH, Lannon MM, Lopes A, et al. High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study. Bone Marrow Transplant 2019;54:465–468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Blystad AK, Enblad G, Kvaløy S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001;27:711–716.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004;33:405–410.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40:443–450.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Rodríguez J, Conde E, Gutiérrez A, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007;18:652–657.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Rodríguez J, Conde E, Gutiérrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79:32–38.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019;125:1507–1517.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Schmitz N, Truemper L, Bouabdallah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 2021;137:2646–2656.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Yam C, Landsburg DJ, Nead KT, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol 2016;91:672–676.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 2018;29:715–723.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Kitahara H, Maruyama D, Maeshima AM, et al. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. Ann Hematol 2017;96:411–420.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Pellegrini C, Argnani L, Broccoli A, et al. Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. Oncologist 2014;19:746–750.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    El-Galaly TC, Pedersen MB, Hutchings M, et al. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: a review of 124 patients. Am J Hematol 2015;90:975–980.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Horwitz S, Coiffier B, Foss F, et al. Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 2015;26:774–779.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Tomita N, Hattori Y, Fujisawa S, et al. Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. Ann Hematol 2015;94: 431–436.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Cottereau AS, El-Galaly TC, Becker S, et al. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients. J Nucl Med 2018: 59:589–595.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Mehta-Shah N, Ito K, Bantilan K, et al. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Adv 2019;3:187–197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Schmitz C, Rekowski J, Müller SP, et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. Hematol Oncol 2020;38:244–256.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824–1833.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:2171–2180.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Meignan M, Gallamini A, Itti E, et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:1876–1881.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Rodríguez J, Caballero MD, Gutiérrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003;14:1768–1775.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120: 978–985.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134:202–207.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Chen AI, McMillan A, Negrin RS, et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008;14:741–747.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013;31:3100–3109.

  • 96.

    Beitinjaneh A, Saliba RM, Medeiros LJ, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant 2015;21:855–859.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Domingo-Domènech E, Boumendil A, Climent F, et al. Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the lymphoma working party (LWP) of the EBMT. Bone Marrow Transplant 2020;55:796–803.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:2172–2176.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008;26:2264–2271.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27:3951–3958.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Dodero A, Spina F, Narni F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012;26:520–526.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Epperla N, Ahn KW, Litovich C, et al. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol 2019;12:6.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Domingo-Domènech E, Boumendil A, Climent F, et al. Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2020;55: 633–640.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Lansigan F, Horwitz SM, Pinter-Brown LC, et al. Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry. Acta Haematol 2020;143:40–50.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–2196.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2017;130:2709–2717.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095–3100.

  • 108.

    Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631–636.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 2014;7:11.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol 2015;33:2492–2499.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013;31:104–110.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182–1189.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Horwitz SM, Mehta-Shah N, Pro B, et al. Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma from the phase 2 primo Trial: selection of regimen for the dose-expansion phase [abstract]. Blood 2019;134(Supplement_1):134. (Abstract 1567)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Brammer JE, Zinzani PL, Zain J, et al. Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 Primo Trial: results of an interim analysis. [abstract] Blood 2021;138(Supplement 1):138. (Abstract 2456)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 2018;131:888–898.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Gambacorti-Passerini C, Orlov S, Zhang L, et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study. Am J Hematol 2018;93:607–614.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group study. J Clin Oncol 2017;35:3215–3221.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Bossi E, Aroldi A, Brioschi FA, et al. Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. Am J Hematol 2020;95:E319–E321.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial. Cancer Sci 2020;111:4540–4547.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Reed DR, Hall RD, Gentzler RD, et al. Treatment of refractory ALK rearranged anaplastic large cell lymphoma with alectinib. Clin Lymphoma Myeloma Leuk 2019;19:e247–e250.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Tomlinson SB, Sandwell S, Chuang ST, et al. Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib. Leuk Res 2019;83:106164.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920–2924.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702–703.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293–4297.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Advani R, Horwitz S, Zelenetz A, et al. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007;48:521–525.

  • 126.

    Wang X, Zhang D, Wang L, et al. Cyclosporine treatment of angioimmunoblastic T-cell lymphoma relapsed after an autologous hematopoietic stem cell transplant. Exp Clin Transplant 2015;13:203–205.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21:860–863.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 2015;121:716–723.

  • 129.

    Morschhauser F, Fitoussi O, Haioun C, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013;49:2869–2876.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Horwitz S, Moskowitz C, Kewalramani T, et al. Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat [abstract]. Blood 2005;106: (Abstract 2679).

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Connors JM, Sehn LH, Villa D, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) as secondary chemotherapy in relapsed/refractory peripheral T-cell lymphoma [abstract]. Blood 2013;122:: Abstract 4345.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Park BB, Kim WS, Suh C, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 2015;94:1845–1851.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Qian Z, Song Z, Zhang H, et al. Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma. BioMed Res Int 2015;2015:606752.

  • 134.

    Stuver RN, Khan N, Schwartz M, et al. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Hematol 2019;94:641–649.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2022 by the National Comprehensive Cancer Network 2022
Page Numbers:
24
Article Category:
Other
Print Publication Date:
01 Mar 2022
Online Publication Date:
Mar 2022

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 26710 5904 710
PDF Downloads 20646 4331 300
EPUB Downloads 0 0 0